Induced exon inclusion in spinal muscle atrophy
The invention relates to the use of an antisense compound for inducing exon inclusion as a treatment for Spinal Muscle Atrophy (SMA). More particularly it relates to inducing inclusion of exon 7 to restore levels of Survival Motor Neuron (SMN) protein encoded by the Survival Motor Neuron (SMN) gene.
1. A method of enhancing the level of exon 7-containing SMN2 mRNA relative to exon-deleted SMN2 mRNA in a cell, comprising contacting the cell with an antisense oligonucleotide, wherein the antisense oligonucleotide comprises a sequence of from 14 to 21 nucleotides, from 15 to 25 nucleotides, or from 20 to 30 nucleotides in length which specifically hybridizes to a region within the SMN2 pre-mRNA selected from within exon 7, intron 7, exon 8, a portion of intron 7, and a portion of exon 8 of the SMN2 pre-mRNA, wherein the antisense oligonucleotide is a morpholino oligonucleotide comprising:
at least one internucleoside linkage that is positively charged at physiological pH, wherein the at least one nucleotide has the formula:
wherein Nu is a nucleobase;
R x is selected from the group consisting of HO—, a nucleotide, and piperazinyl;
R y is selected from the group consisting of hydrogen, a C 1 -C 6 alkyl, a nucleotide, a peptide moiety, an amino acid, a formamidinyl moiety, and acyl; and,
R z is selected from the group consisting of null, hydrogen, a C 1 -C 6 alkyl, and acyl; and pharmaceutically acceptable salts thereof,
wherein the sequence is selected from: SEQ ID NO:2-8, 10-18, 20-25, 27-32, 34-41, 43-52, 54-61, 63-69, and 71-79.
2. The method of claim 1 , wherein the antisense oligonucleotide comprises a sequence of from about 14 to about 21 nucleotides.
3. An antisense oligonucleotide comprising a sequence selected from 14 to 21 nucleotides, from 15 to 25 nucleotides, and from 20 to 30 nucleotides in length which specifically hybridizes to a region within the SMN2 pre-mRNA selected from within exon 7, intron 7, exon 8, a portion of intron 7, and a portion of exon 8 of the SMN2 pre-mRNA, such that the level of exon 7-containing SMN2 mRNA relative to exon 7-deleted SMN2 mRNA in the cell is enhanced, wherein the antisense oligonucleotide is a morpholino oligonucleotide comprising: at least one nucleotide comprising an internucleoside linkage that is positively charged at physiological pH,
wherein the at least one nucleotide is of the formula:
wherein Nu is a nucleobase;
R x is selected from the group consisting of HO—, a nucleotide, and piperazinyl;
R y is selected from the group consisting of hydrogen, a C 1 -C 6 alkyl, a nucleotide, a peptide moiety, an amino acid, a formamidinyl moiety, and acyl; and,
R z is selected from the group consisting of null, hydrogen, a C 1 -C 6 alkyl, and acyl; and pharmaceutically acceptable salts thereof,
wherein the sequence is selected from: SEQ ID NO:2-8, 10-18, 20-25, 27-32, 34-41, 43-52, 54-61, 63-69, and 71-79.
4. The antisense oligonucleotide of claim 3 , wherein the sequence is complementary to a target region within intron 7 of the SMN2 pre-mRNA.
5. The antisense oligonucleotide of claim 3 , wherein the sequence is complementary to a portion of intron 7 and exon 8 of the SMN2 pre-mRNA.
6. The antisense oligonucleotide of claim 3 , wherein the sequence is from about 14 to about 21 nucleotides.
7. The antisense oligonucleotide of claim 3 , wherein the antisense oligonucleotide further comprises a peptide moiety which enhances cellular uptake.
8. The antisense oligonucleotide of claim 7 , wherein the peptide is an arginine rich peptide.
9. A method of treating spinal muscular atrophy (SMA) in a patient, comprising administering to the patient an antisense oligonucleotide according to claim 3 , thereby treating the patient.